Ixchiq (VLA1553 / Chikungunya live-attenuated vaccine) (Chikungunya Vaccine)

Development Phase Approved / Licensed Primary Status

Platform Technology Biological (unspecified platform) Biologic Architecture

Target Indication Chikungunya Pathogen / Antigen

Last Verified 2026-08-01 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority	Status & Details
US FDA	Approved / Authorized Date: 2023-11-09FDA accelerated approval for individuals 18+ at high risk of chikungunya virus exposure
EMA (Europe)	Approved / Authorized Date: 2024-06-28EMA approved for active immunization of individuals 18+
Health Canada	Approved / Authorized Date: 2024-06-14Health Canada approved
TGA (Australia)	Under Regulatory Review Date: 2024-09-01TGA submission under evaluation

Scientific Profile & Documentation

Platform Architecture: Biological (unspecified platform)
Lead Developer: Valneva Austria GmbH
Next Expected Milestone: Post-marketing safety surveillance; adolescent trial data readout
Analyst & Development Notes: Auto-grouped from 3 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation: ClinicalTrials.gov NCT06028841 →
Additional Sources & Literature: NCT07133178 on ClinicalTrials.gov (2026-07-10)
NCT04838444 on ClinicalTrials.gov (2026-07-10)

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT06028841 Approved / Licensed

A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

Status: Active / Ongoing • Expected Readout: 2024-08-27

NCT07133178 Approved / Licensed

A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

Status: Active / Ongoing • Expected Readout: 2026-12

NCT04838444 Approved / Licensed

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

Status: Active / Ongoing • Expected Readout: 2023-03-03

Milestone Overview

Stage Verification

Approved / Licensed confirmed as of 2026-08-01.
Target Milestone

Post-marketing safety surveillance; adolescent trial data readout

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.